ISRCTN16782845 https://doi.org/10.1186/ISRCTN16782845

# A randomised, double-blind, placebo-controlled, cross-over pilot study using nabilone for symptomatic relief in patients with Huntington's disease

**Submission date**
07/09/2005

**Recruitment status**
No longer recruiting

**Registration date**
13/09/2005

**Overall study status**
Completed

**Last Edited**
01/02/2013

**Condition category**
Nervous System Diseases

[ ] Prospectively registered
[ ] Protocol
[ ] Statistical analysis plan
[X] Results
[ ] Individual participant data

**Plain English summary of protocol**
Not provided at time of registration

## Contact information

**Type(s)**
Scientific

**Contact name**
Dr Hugh Rickards

**Contact details**
Queen Elizabeth Psychiatric Hospital
Vincent Drive
Edgbaston
Birmingham
United Kingdom
B15 2QZ
+44 (0)121 678 2019
hugh.rickards@bsmht.nhs.uk

## Additional identifiers

**Protocol serial number**
Sponsor 583; Eudract test 0000632-21

## Study information

### Scientific Title

### Study objectives
That nabilone will have a beneficial effect on movement and psychiatric symptoms in patients with Huntington's disease

### Ethics approval required
Old ethics approval format

### Ethics approval(s)
Not provided at time of registration

### Study design
Randomised double blind placebo controlled crossover group trial

### Primary study design
Interventional

### Study type(s)
Treatment

### Health condition(s) or problem(s) studied
Huntington's disease

### Interventions
Nabilone or placebo for 5 weeks, 5 week washout period cross over to nabilone or placebo for 5 weeks

### Intervention Type
Drug

### Phase
Not Specified

### Drug/device/biological/vaccine name(s)
Nabilone

### Primary outcome(s)
Motor symptoms rated using the motor scale from the UHDRS

### Key secondary outcome(s))
Psychiatric symptoms rated using the behavioural assessment of the UHDRS and the NPI

### Completion date
01/12/2006

## Eligibility

### Key inclusion criteria

Competent patients with a clinical diagnosis of Huntington's disease over 18

### Participant type(s)
Patient

### Healthy volunteers allowed
No

### Age group
Adult

### Lower age limit
18 years

### Sex
All

### Key exclusion criteria
1. Under 18
2. Known allergy to cannabinoids
3. Liver dysfunction
4. Personal or family history of psychosis
5. Heart disease or hypertension
6. Pregnant or lactating

### Date of first enrolment
01/09/2005

### Date of final enrolment
01/12/2006

## Locations

### Countries of recruitment
United Kingdom

England

### Study participating centre
**Queen Elizabeth Psychiatric Hospital**
Birmingham
United Kingdom
B15 2QZ

## Sponsor information

**Organisation**
Birmingham and Solihull Mental Health Trust (UK)

**ROR**
https://ror.org/00cjeg736

# Funder(s)

**Funder type**
Industry

**Funder Name**
Cambridge Laboratories (UK) - hold the European marketing rights for nabilone

# Results and Publications

**Individual participant data (IPD) sharing plan**

**IPD sharing plan summary**
Not provided at time of registration

**Study outputs**

| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Results article | results | 15/11/2009 | | Yes | No |